We are live on ! Find out more
IPHA

Innate Pharma
IPHA

8 hedge funds and large institutions have $806K invested in Innate Pharma in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital invested

Capital invested by funds: $736K → $806K (+$69.9K)

0.1% more ownership

Funds ownership: 0.29% → 0.4% (+0.1%)

11% less funds holding

Funds holding: 9 → 8 (-1)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
8
Holders Change
-1
Holders Change %
-11.11%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Optiver Holding
Optiver Holding
Netherlands
+$318K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$41.7K
2
ETC
Exchange Traded Concepts
Oklahoma
-$21.8K
3
Millennium Management
Millennium Management
New York
-$7.26K
4
Morgan Stanley
Morgan Stanley
New York
-$6.14K

IPHA Hedge Fund Activity: Q3 2023 in Review

8 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q3 2023, worth a combined $806K — up 9.5% from $736K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of IPHA and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.

The largest buyer was Optiver Holding, adding an estimated $318K. The largest seller was Citadel Advisors, exiting entirely with an estimated $41.7K sold.

  • 8 institutional investors held Innate Pharma (IPHA) as of Q3 2023, down from 9 in Q2 2023.
  • Funds reported $806K of Innate Pharma stock for Q3 2023, up 9.5% quarter-over-quarter.
  • 0 funds opened new Innate Pharma positions in Q3 2023 and 1 closed out, a net change of -1 holder.
  • The largest Innate Pharma buyer in Q3 2023 was Optiver Holding, an estimated $318K added.
  • The largest Innate Pharma seller in Q3 2023 was Citadel Advisors, an estimated $41.7K sold.

Based on aggregated 13F filings for Q3 2023.